Enlivex Ltd. (NasdaqCM: ENLV)
Health Care · Biotechnology · IL
$1.52
+3.40% today · -90.9% 1Y
Enlivex Ltd. (NasdaqCM: ENLV) operates in the Biotechnology industry within the Health Care sector. The company is valued at $25.70M and employs 34 people.
Over the last twelve months the share price has lost 90.9%, trading between 1.39 and 27.15.
Tweenvest scores Enlivex Ltd. across four factors: quality 27/100. Its strongest factor is quality.
ENLV price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $25.70M
- Revenue (TTM)
- —
- P/E
- 0.00
- EPS
- 382.20
- Dividend yield
- —
- Beta (5Y)
- 1.46
- 52-week high
- $27.15
- 52-week low
- $1.39
- Avg volume (3M)
- —
- Shares outstanding
- 17.49M
- Employees
- 34
- Next earnings
- —
About Enlivex Ltd.
Enlivex Therapeutics Ltd., established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is currently advancing Allocetra, its flagship cell-based therapeutic. This treatment is undergoing Phase II clinical evaluation for its effectiveness in addressing organ dysfunction and failure that arises from sepsis. Additionally, Allocetra is being investigated in preclinical studies for its potential application in solid tumor therapy.
- ISIN
- IL0011319527
- Founded
- 2005
- Listed since
- Jul 31, 2014
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €879.20 | +1.74% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $158.83 | +14.36% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.